Tagged with M

Cegedim Strategic Data Malaysia Nowadays we can talk of an abundance of information coming from companies like Frost& Sullivan, IMS and even consultancies who are producing their own data. As a leader in market research how can CSD find a space within this picture and what strategies does it employ to stay ahead of…

Top Institute Pharma There is a very interesting history behind the origins of Top Institute Pharma (TI Pharma) as it aligned the interests of both the World Health Organization (Priority Medicines) and the EU’s Lisbon Strategy. Lisbon’s goal in 2000 was to transform the EU into the most powerful knowledge economy by 2010…

Lundbeck Limited (UK) If we look at Lundbeck globally, the company has been doing very well. Last year was a record year for profits. From a UK perspective, can you provide an overview of how you have seen the company performing since you arrived in 2009, and what your outlook is for 2011?…

Vifor Pharma UK Ltd You joined Vifor Pharma to establish a new structure in the UK. It is quite difficult to set up a new enterprise—what have been the main challenges for yourself and the organization in the year since Vifor Pharma UK came into being? I was actually the first employee of Vifor…

Lundbeck Malaysia You have worked in the pharmaceutical industry for many years starting with Novartis and you have spent the last eight years working for Lundbeck. What are the major changes that you have observed in the Malaysian pharmaceutical industry over that time? The industry’s approach has changed in its dealing with…

Sanofi Aventis Malaysia Pharmaceutical Executive is a magazine about executives, their experience and their perspectives on the pharmaceutical industry. You have worked in Australia, Hong Kong and now you are the general manager of Malaysia, Singapore and Brunei. For the interest of our readers could you give an overview of what path you…

IMS Health Malaysia You spent most of your career in the pharmaceutical industry with Bristol Meyers Squibb and earlier on for NV Organon which you joined in 1998. In 2007 you left to join the world of consultancy, how useful was this insider knowledge to your work and what is it like now…

Alliance Pharma Plc Today, Alliance Pharma Plc. represents a true pharmaceutical success story in the UK, distributing to 24 countries and moving towards GBP 50m annual turnover in just twelve years. If we take a look back in time, can you explain what your drivers were to set up the company in 1998?…

Bristol-Myers Squibb UK Before joining Bristol-Myers Squibb (BMS), you have spent roughly twenty years with GSK. Can you describe the trajectory of your career and explain what attracted you in BMS? Before joining BMS 4 years ago and even before spending those twenty years with GSK, I had already worked for Sanofi-Aventis for…

Amgen B.V. You are still relatively new to the Netherlands having been here for one year. This must be a very insightful experience abroad. What were your initial expectations and first impressions when first starting here and how have they evolved over the course of your year as head of Amgen in…

Eli Lilly Malaysia You have spent much of your time working in the USA and came to Malaysia in 2008 as Country Manager. What were your expectations of Malaysia before you arrived and how have you enjoyed adapting to this ethnically diverse country? The opportunity has been enjoyable on a number of levels.…

Astellas Pharma Ltd. Astellas’s European headquarters is based in the UK. What does the UK market represent for the company? Speaking from a global perspective, 60% of Astellas’ business is based in Japan and Asia. Approximately 20% is in the U.S.; and approximately 20% is in Europe. So Europe still represents a vast—and…